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Abstract
Background: Ghana changed their antimalarial drug policy from monotherapies to Artemisinin-based Combination
Therapies in 2004 in order to provide more efficacious medicines for treatment of malaria. The policy change can be
eroded if poor quality Artemisinin-based Combination Therapies are allowed to remain on the Ghanaian market
unchecked by regulatory bodies and law enforcement agencies. The presence and prevalence of substandard and
counterfeit Artemisinin-based Combination Therapies need to be determined on open markets in Ghana; a review of the
current policy; identifying any gaps and making recommendations on actions to be taken in addressing gaps identified
are essential as the data provided and recommendations made will help in ensuring effective control of malaria in Ghana.
Methods: A field survey of antimalarial drugs was conducted in the central part of Ghana. The amount of active
pharmaceutical ingredient in each Artemisinin-based Combination Therapy sample identified in the survey was
measured using high performance liquid chromatographic analyses. Active pharmaceutical ingredient within the
range of 85–115 % was considered as standard and active pharmaceutical ingredient results out of the range were
considered as substandard. All samples were screened to confirm stated active pharmaceutical ingredient
presence using mass spectrometry.
Results: A total of 256 Artemisinin-based Combination Therapies were purchased from known medicine outlets,
including market stalls, hospitals/clinics, pharmacies, drug stores. Artemether lumefantrine (52.5 %) and artesunate
amodiaquine (43.2 %) were the predominant Artemisinin-based Combination Therapies purchased. Of the 256
Artemisinin-based Combination Therapies purchased, 254 were tested, excluding two samples of Artesunate-SP.
About 35 % of Artemisinin-based Combination Therapies were found to be substandard. Nine percent of Artemisinin-
based Combination Therapies purchased were past their expiry date; no counterfeit (falsified) medicine samples were
detected by either high performance liquid chromatographic or mass spectrometry.
Conclusion: A high proportion of Artemisinin-based Combination Therapies sold in central Ghana were found to be
substandard. Manufacturing of medicines that do not adhere to good manufacturing practices may have contributed
to the poor quality of the Artemisinin-based Combination Therapies procured. A strict law enforcement and quality
monitoring systems is recommended to ensure effective malaria case management as part of malaria control.
Keywords: Ghana, Malaria, Artemisinin-based combinations, Counterfeit medicines, Falsified medicines, Substandard
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Background
Though the therapeutic effectiveness of medicines to
cure common tropical diseases in Africa is a poverty re-
medial measure, the integrity of these medicines is crit-
ical in successfully combating the diseases they target
[1, 2]. Counterfeit and substandard medicines pose a
stumbling block to public health delivery systems for
malaria in endemic countries, [3–5]. Meta-analysis of
existing data reported roughly 30 % poor quality medi-
cines in South East Asia and sub-Saharan Africa [2].
Malaria and microbial infections are the leading causes
of morbidity and mortality in Ghana [6, 7]. Malaria,
alone, accounts for about 40 % of outpatient visits in the
country and has significantly contributed to morbidity in
all age groups [8, 9].
Concerns have recently been raised in Ghana and sev-
eral other African countries about resistance to pre-
scribed medicines for treatment of diseases [10]. Among
reasons for the loss of medicines efficacy are resistance
of pathogens to medicines that were previously effective;
non-compliance of patients to treatment and dosage re-
gimes and proliferation of counterfeit and/or substand-
ard medicines [4, 11].
Since the introduction of Artemisinin-based Combin-
ation Therapy (ACT) in Ghana in 2004, there has been
proliferation of different brands of ACTs on the
Ghanaian market. It is perceived that some of the ACTs
could be either counterfeits or substandard [12]. Sur-
veillance on poor quality medicines could potentially be
insufficient in Ghana to address this challenge, thus
putting the lives of many Ghanaians at risk [13–16].
The situation is being exacerbated by the culture of in-
discriminate ‘over the counter sale’ of all categories of
medicine in the country [16, 17].
In response to recent reports in the Ghanaian media
[18] of poor quality ACTs, we purchased following the
mystery shopping strategy, all types of ACTs available in
predominantly rural communities in the middle part of
Ghana, in order to determine their quality using chro-
matographic methods established at the London School
of Hygiene & Tropical Medicine (LSHTM) and the
Georgia Institute of Technology, Atlanta, USA [19].
Methods
Study area
A cross-sectional survey was carried out between January
2011 and June 2011 in the Kintampo Health Research
Centre (KHRC) study area located in 8 neighbouring dis-
tricts, made up of Kintampo North, Kintampo South,
Nkoranza North, Nkoranza South, Techiman North,
Techiman South, Tain and Wenchi in the central part of
Ghana. These districts are predominantly rural with close
to 80 % of the resident population living in rural commu-
nities. The tribal groups mainly consist of Bono and Mo
origins with a significant part of residents having migrated
from the northern parts of the country. The occupation is
mainly subsistence farming of crops such as yam, cassava
and maize [20]. Malaria is the disease of highest burden in
the area. [21–23].
The health systems in these districts are largely basic
and modelled so that they follow a uniform pattern used
in district health systems in Ghana. The lowest level
(referred to as level A) of health care is at the commu-
nity level and manned by Community Health Nurses.
The next level is Health Centre level (referred to as level
B), where middle level health professionals (physician as-
sistant, midwife, nurses, laboratory and dispensary tech-
nicians are in charge of the system. The district hospital
is level C and employs senior-level health professional
including physicians, anaesthetists, senior nurses/mid-
wifes, pharmacists and laboratory technologists. Patients
presenting at the lower level with any condition that
cannot be managed are referred to the next level for
management; with cases beyond district hospitals re-
ferred to regional hospitals or teaching hospitals. Health
seeking by most community members needing treat-
ment, however, does not always follow this conventional
arrangement as home treatment of malaria using drugs
purchased from licensed chemical sellers is the com-
monest health seeking behaviour [24–26].
The study area consisted of 237 medicine outlets
(MO); these comprised 37 health facility dispensaries,
eight pharmacies and 192 license chemical shops.
Mobile vendors and some grocery shops, drinking bars
and homes were other sources of medicine sales; these
were mostly accessible to community members since
they are located within the community. The quality of
drugs are to be regulated by the Ghana Food and Drugs
Authority in collaboration with the Pharmacy Council of
Ghana and various security agencies (including police,
Customs Excise & Preventive Services among others) are
charged with ensuring that only quality medicines are
available on the market.
Medicine outlet selection
The Kintampo Health and Demographic Surveillance
database, which has geolocations of all communities,
MOs and health facilities, was used to create MO clus-
ters. Cluster A included MOs within a 5-km radius from
a district/municipal hospital, cluster B included MOs
within 5–10 km radius from a district/municipal hospital
and cluster C included MOs >10 km from a district/mu-
nicipal hospital. Within each cluster, 10 MOs were ran-
domly selected if the number of known MOs was less
than forty and 20 MOs were randomly selected if the
number of outlets was 40 or higher. All pharmacies
were, however, purposively selected for medicines to be
purchased due to their limited number [8] in the studied
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area. All mobile vendors and other outlets in the se-
lected communities were included for medicine procure-
ment. Medicines outlets were stratified by clusters as
defined above and 141 of these outlets were randomly
selected from a total of 237 medical outlets within the
study.
A “mystery shopping” strategy was used to buy ACTs
from the selected shops [19]. Trained mystery shoppers
were made to visit each selected MO, present themselves
as a client with malaria symptoms and engage the shop
attendant in a discussion regarding what antimalarials
were available for sale to clients. From the list communi-
cated, the mystery shopper purchased some of the ACTs
available in stock and then made a mental note of all
other ACTs that were available and could be obtained
from the MO. The information was then relayed to an-
other mystery shopper who later visited the shop to pur-
chase the other brands of ACTs available in the shop.
The process of mystery shopping was repeated in all
identified shops until samples of all brands of ACTs
available in each selected shop were obtained. The
trained shoppers carried through this process in such a
way that there was never any suspicion by the sellers.
Mystery shoppers wrote down the description of the
outlet on exiting the MO. ACTs purchased were trans-
ported to the Kintampo Health Research Centre Phar-
macy on daily basis. All samples purchased were stored
as per the manufacturer’s instructions by the study
pharmacist.
The Regional Medical Store was visited to ascertain
the state and storage conditions of ACTs that were in
stock.
Samples were shipped within two months to the bioa-
nalytical facility at the London School of Hygiene and
Tropical Medicine (LSHTM) for analysis. The packaging
on each sample was scanned electronically and/or
photographed at LSHTM and a detailed description of
the ACT was recorded on a Microsoft Excel spreadsheet.
The description included brand name, stated active in-
gredients, dose form, date of purchase from MO, name
of manufacturer, country of origin, batch number, expiry
date, number of tablets per packet and retail price paid.
The database created together with the scans of the
packets and their contents was shared with the Ghana
team.
Chemical content analysis and classification of samples
Laboratory assessment of the quality of ACTs purchased
in the central part of Ghana was carried out at the
London School of Hygiene and Tropical Medicine
(LSHTM) and the Georgia Institute of Technology (GT).
Sample packaging and appearance were assessed, coded
and recorded, as well as the weight, and dimensions of
each sample. The amount of active pharmaceutical
ingredient (API) in each sample was determined using
high performance liquid chromatography (HPLC) and
the presence of any compounds other than the stated
APIs was screened by ambient mass spectrometry (MS)
following published methods [19]. Formulations were
analysed for the amount of each active pharmaceutical
ingredient (API) present using high performance liquid
chromatography (HPLC). Briefly each tablet was pul-
verised, dissolved in solvent depending on the stated
API; artesunate (AS), artemether (AM), dihydroartemisi-
nin (DHA), amodiaquine (AQ) and sulfadoxine/pyri-
methamine (SP) were dissolved in methanol; samples
containing lumefantrine (LUM) were dissolved in 10 %
acetic acid in methanol, and piperaquine (PIP) in metha-
nol/0.1 M HCl (1:1; v/v). Solvent extracts were sonicated
followed by centrifuging, and the supernatant injected
into the HPLC column to determine the amount of API
present.
HPLC analysis was conducted using a Dionex Ultimate
3000 system (Thermofisher, Hemel Hempstead, UK) and
separation achieved using a GENESIS AQ 4 μm column
(150 × 4.6 mm, Grace Materials Technologies, Cranforth,
UK). The mobile phase was a gradient of ammonium for-
mate (10 mM, pH 2.7) and acetonitrile (v/v; 60:40 to 85:15
over 7.0 min). A photo-diode array unit (UV-PDA; DAD
3000) was set at 204 nm for the artemisinin derivatives
(AS, AM, DHA), 360 nm for PIP, AQ and LUM. In all
cases, the flow rate used was 1.0 ml/min. Calibration
curves of each compound were generated by Thermo-
fisher Scientific Dionex Chromeleon 7.2 chromatography
data system (CDS) software using known amounts of the
corresponding chemical standards. Reference standards of
artemisinin, artesunate, artemether, dihydroartemisinin,
amodiaquine dichlorodihydrate and pyrimethamine were
purchased from Sigma Aldrich, UK. Lumefantrine was
purchased from WHO, Switzerland. Results were
expressed as a percentage of the stated amounts of API on
the package.
Quality of ACT was assessed by comparing the
amount of API detected with that stated on the pack-
aging label and indicated as a percentage of the stated
value.
We adopted a range between 85 % and 115 % of the
stated API content for both compounds in the ACT to
classify samples as being of acceptable quality. Medicines
with less than 85 % or over 115 % of the stated API con-
tent of any of the partner compounds were therefore
classified as substandard.
Data management and analysis
The questionnaires completed by mystery shoppers as
well as basic data collected by the pharmacist were
double-entered, range and consistency checks and verifi-
cation were carried out using Microsoft Access. The
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sampling was randomised and all data were cleaned and
analyzed using STATA version 11 (Stata Corp., TX
USA). Simple descriptive analysis such as proportions
are used to summarize various variables including the
prevalence of substandard drugs. Bar graphs were used
to summarize some results such as sources of ACTs and
country of their origin using Microsoft Excel.
Results
ACTs were found in 107 out of the 141 selected MOs.
The majority (81.3 %) of MOs visited were license
Chemical Sellers Shops (Table 1).
Two hundred and fifty six ACT samples were pur-
chased by the mystery shoppers. Approximately 9 % of
the ACTs purchased had already expired. Artemether-
lumefantrine (AL) and artesunate-amodiaquine (AA)
were the leading ACTs in the market (Table 2). A few
Licensed Chemical Sellers shops and pharmacy shops
also had dihydroartemisinin piperaquine (DHAP) in
stock. All AA samples purchased were coblistered.
It was found that 35.4 % (90/254) of the ACTs were
substandard and failed to comply with the required
amount of APIs (Table 3). This means that only 64.6 %
(164/254) were in the recommended API range (Table 3).
No grossly counterfeit (falsified) medicine samples were
detected by either HPLC or MS. Only two samples,
artesunate-SP, were found and purchased at the sampled
MOs, but these were not tested for logistics reasons.
In order to document the contribution of ACT sam-
ples that did not comply with the amount of stated API,
the component of each brand of ACT was quantified.
For samples stated to contain artesunate, 22.5 % (25/
111) had the artemisinin components at levels lower
than the stated API content. Also 4.5 % (6/134) of arte-
mether samples tested had artemether components at
levels lower than the stated API content (Table 4). On
the contrary, none (0/111) and 1.5 %(2/134) of samples
tested had artemisinin and artemether components at
levels greater than the required API content, respectively
(Table 4).
Analysis of other medicines, such as amodiaquine,
used in combination with artemisinin derivatives showed
that 25.2 % (28/111) of samples had contents lower than
that stated. Similarly, 3.0 % (4/134) of samples tested
had lower than required lumefantrine content (Table 5).
Higher than acceptable amodiaquine and lumefantrine
content was found in 13.8 % and 30.1 % of the tested
ACT samples, respectively (Table 5).
About 52 % of ACT market share is taken up by three
pharmaceutical companies (Fig. 1).
ACTs labelled with India as the country of origin com-
prised the highest proportion (61.54 %) of substandard
ACTs (Fig. 2). This was followed by ACTs produced in
Ghana (23.1 %), China (7.7 %) and Morocco (7.69 %).
Discussion
Malaria remains the most frequent reason for seeking
healthcare in Ghana and registers the highest level of
mortality [27]. In 2004, Ghana changed malaria policy
from the use of monotherapies to ACT. This study was
carried out in response to increasing anecdotal reports
of substandard and counterfeit ACTs in the Ghanaian
market since the start of implementation of policy
changes in 2005 [28].
The prevalence of substandard ACTs was relatively
high; 35.4 % of all ACTs purchased were substandard
and contained less than the stated amount of API.
Specifically, the majority of substandard artesunate-
amodiaquine ACTs had lower than expected levels of
artesunate, the more expensive API. Reasons that could
have led to this high prevalence of substandard ACTs in-
clude poor compliance with Good Manufacturing Prac-
tices (GMP) and/or poor storage conditions along the
supply chain. The relative contribution of these two fac-
tors could not be ascertained easily and is beyond the
scope of this study.
Artemether-lumefantrine (AL) and artesunate-
amodiaquine (AA) were the commonest ACTs on the
market and are the ones recommended by the Ghana
National Malaria Control Programme (GNMCP); how-
ever the investigators were unable to ascertain if all the
brands and batches purchased in this survey had been
registered with the Ghana Food and Drugs Authority
(GFDA). A set of all samples of ACTs purchased have,
however, been shared with GFDA. It is also possible that
some of these medicines were not officially approved.
ACTs found in the Ghanaian markets are not unique to
Ghana but can also be found in other malaria endemic
countries. Levels of poor quality ACTs comparable to
those reported in this manuscript have also been found in
Asia and other parts of Africa, as wide networks and dis-
tribution channels already exist; it therefore means that is-
sues regarding poor quality medicines are global in nature
and require serious attention. Studies carried out in
Table 1 Types and availability of ACTs in the Medicine outlets
surveyed
Drug Outlet Total number of outlets
visited stocking ACTs
% outlets
stocking ACTs
License Chemical Shops 87 81.3
Pharmacy 7 6.5
Health Facility 7 6.5
Mobile vendor 2 1.9
Othera 4 3.8
Total 107 100.0
aOther comprised of drinking bars, grocery shops, homes and mark
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Southeast Asia (e.g. Cambodia, Laos, Myanmar, Thailand,
Vietnam, China and Indonesia) and Africa (e.g. Senegal,
Madagascar, Uganda, Burkina Faso, Nigeria and Ghana)
[29–35] confirm high amounts of substandard antimalar-
ials in circulation. Adherence to rules and regulations re-
garding importation and in-country manufacture of ACTs
has led to minimal levels of substandard and virtually
non-existence of counterfeit ACTs in countries such as
Ethiopia and Rwanda [32]. The main outstanding chal-
lenge in Ethiopia has been to ensure that all medicines are
registered to rule out any vulnerability towards penetra-
tion of poor quality products [32].
Recent research on ACTs has shown that products
from WHO-approved manufacturers can be reported to
be up to five times less likely to fail basic quality tests
[36]. It is therefore important that a thorough audit be
carried out on all manufacturers who are without WHO
approval. A strong regulatory system is key in preventing
substandard drugs entering the consumer market. In
Rwanda there is an existing mandatory system for all
manufacturers to provide a current WHO-approved cer-
tificate of Good Manufacturing Practice before the Min-
istry of Health can award contracts to those qualified to
supply medicines. Rwanda uses only WHO-approved
certified manufacturers [36], and this has helped in en-
suring high quality standard ACTs prevail in the mar-
kets. Other countries should emulate Rwanda’s tight
processes where its bureau of standards verifies, docu-
ments and together with their customs services depart-
ment and ministry of health, inspects all medications
imported into the country. Where poor quality
medicines are found, medicine regulatory authorities
partner with Rwandan police force and Interpol to target
the organized criminals responsible, whenever possible.
Thus, Rwanda’s drug quality control strategy depends
not only on its health system, but also on its law en-
forcement and justice systems [37].
The sources of substandard ACTs found in the study
area are global as substandard ACTs from all ACT man-
ufacturers were observed. Substandard ACTs were iden-
tified from pharmaceutical companies in both Africa and
Asia with notable countries being India, Ghana, China
and Morocco (Fig. 2). A concerted effort by Ghanaian
authorities will be required in this regard to drive the re-
duction and eventual extermination of both production
and importation of poor quality ACTs.
Co-blistered artesunate-amodiaquine was the com-
monest ACT formulation found in the Ghanaian market.
To improve on compliance, it should be the highest pri-
ority of pharmaceutical companies to replace co-
blistered formulations with co-formulated ones, as pa-
tients can be selective towards the artemisinin compo-
nent at the expense of the amodiaquine one, thereby
increasing the likelihood of developing Plasmodium
parasite strains resistant to artemisinins.[28, 38, 39].
Regional medical stores, government dispensaries and
other pharmacies located in the study area were not
compliant to the Ghana national drug poilcy require-
ments [40], as there was no thorough adherence to best
practices involving the equipment, design and regular
maintenance of medicine storage facilities. Records of
GFDA monitoring visits in most of the facilities sampled
could not be readily found. Also, some facilities had ex-
pired medicines in stock that should have been disposed
of in accordance with national guidelines [40].
Proliferation of substandard ACTs into the country
was observed in this survey.
When the policy and programme response against
counterfeit and substandard ACTs was reviewed, it was
noticed that documentations on monitoring and surveil-
lance on medicines supply chains existed. These included
procurement, storage conditions and distribution net-
works. The role of pharmacists, licensed chemical sellers,
Table 2 Types of ACTs purchased from the various medicine outlets (MO)
Type of ACT Health Facilities Licensed chemical shops Pharmacy Mobile vendor Others Total
n (%) n (%) n (%) n (%) n (%) N (%)
AL 4 (21.1) 101 (54.6) 25 (83.3) 3 (42.9) 1 (7.1) 4 (52.3)
AA 15 (78.9) 77 (41.4) 3 (10.0) 4 (57.1) 12 (85.7) 111 (43.4)
DHAP 0 (0.0) 7 (3.8) 2 (6.7) 0 (0.0) 0 (0.0) 9 (3.5)
ASP 0 (0.0) 1 (0.5) 0 (0.0) 0 (0.0) 1 (7.1) 2 (0.8)
TOTAL 19 (100) 186 (100) 30 (100) 7 (100) 14 (100) 256 (100)
Others: include ACTs purchased from drinking spots and homes
AL Artemether-Lumefantrine, AA Artesunate-Amodiaquine, DHAP DihydroartemisininPiperaquine, ASP Artesunate-Sulfadoxine-Pyrimethamine
Table 3 Number of ACTs complying with API quality tests using
High Performance Liquid Chromatography (HPLC)
HPLC results Number Percent
Acceptable for both AD and PM 164 64.6
Acceptable for AD and Substandard for PM 54 21.3
Acceptable for PM and Substandard for AD 23 9.0
Substandard for both AD and PM 13 5.1
Total 254 100.0
Note: AD stands for Artemisinin Derivative, PM stands for Partner medicines
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consumers of the medicines as well as public awareness
programmes were captured in the Ghana drug and anti-
malarials policies as referenced in the Republic of Ghana
National Drug Policy [41] as well as the Anti-malaria Drug
Policy for Ghana [42].
The main reasons attributed to proliferation of sub-
standard ACTs are lack of enforcement of drug policies by
the national regulatory body and law enforcement institu-
tions in Ghana. Resource and capacity constraints contrib-
ute to this less-than-ideal situation [43, 44]. The national
borders remain porous, making it easy for importation of
poor quality medicines into the country, thereby risking
the lives of patients. The roles of the GFDA, Pharmacy
Council of Ghana (PCG) and other authorities (including
Ghana customs, Ghana police etc.) need to be more
clearly defined. These agencies should be empowered to
perform their roles without fear or favour.
It is promising that discussions are currently on-going
among WHO-Member States about quality, safety and
efficacy of antimalarials [45].
The findings of our study may seem re-assuring as
no grossly counterfeit ACTs were detected. Neverthe-
less the high prevalence of substandard ACTs is highly
concerning and should be treated with the highest
public health priority. Most of the patients receiving
these poor quality ACTs live in area without docu-
mented resistance to ACTs, but resistance could de-
velop in future. Furthermore, these patients may not
be appropriately treated for their illness when the
need arises. Routine drug quality monitoring strategies
should be put in place to gain a better understanding
of the extent of the problem and changes that may
occur over time, so that the malaria control
programme can respond with any control measures
needed. Proliferation of poor quality ACTs in malaria
endemic countries has the potential for favouring se-
lection of resistant malaria parasite species that could
otherwise have been treated effectively leading to pro-
gressive loss of confidence in modern medicines by
the Ghanaian populace,
Table 4 HPLC Analysis of Artemisinin derivative (AD) of ACT
Artemisinin
Derivative
Below 85 % Within 85–115 % Above 115 % Total
n (%) n (%) n (%) N = 254
Artesunatea
n (%)
25 (22.5) 86 (77.5) 0 (0.0) 111 (100.0)
Median (IQR) 80.0 (77.2–82.7) 92.9 (89.5–98.6) 0 91.5 (86.0–95.8)
Artemetherb
n (%)
6 (4.5) 126 (94.0) 2 (1.5) 134 (100.0)
Median (IQR) 76.6 (66.8–77.5) 95.9 (92.1–100.4) 116.1 (115.1–117.0) 95.6 (91.5–100.5)
Dihydroartemisinc
n (%)
0 (0.0) 6 (66.7) 3 (33.3) 9 (100.0)
Median (IQR) 0 105.1 (89.2–107.3) 132.4 (120.3–143.2) 107.3 (103.4–120.3)
Combined
n (%)
31 (12.2) 218 (85.0) 5 (2.0) 254 (100.0)
Median (IQR) 78.7 (76.7–82.5) 94.6 (90.9–99.9) 120.3 (117.0–132.4) 93.6 (89.4–99.7)
Note: a, b, cwere derived from Artesunate Amodiaquine. Artemether Lumefantrine and Dihydroartemisinin Piperaquine respectively
Table 5 HPLC results for Partner medicines (PM)
Partner Medicines Below 85 % Within 85–115 % Above 115 % Total N = 254
Amodiaquinea
n (%)
28 (25.2) 64 (57.7) 19 (17.1) 111 (100.0)
Median (IQR) 80.6 (72.6–82.9) 92.7 (88.3–97.2) 118.8 (117.2–121.4) 92.0 (84.9–101.7)
Lumefantrineb
n (%)
4 (3.0) 120 (89.6) 10 (7.5) 134 (100.0)
Median (IQR) 83.3 (77.4–84.4) 99.4 (93.2–105.0) 117.6 (116.2–118.5) 100.3 (93.1–107.1)
Piperaquinec
n (%)
0 (0.0) 3 (33.3) 6 (66.7) 9 (100.0)
Median (IQR) 0 112.1 (111.5–114.7) 121.1 (117.5–123.8) 117.5 (114.7–121.7)
Combined
n (%)
32 (12.6) 187 (73.6) 35 (13.8) 254 (100.0)
Median (IQR) 81.4 (72.8–83.0) 96.6 (91.6–103.4) 118.7 (117.2–120.7) 96.8 (88.9–108.4)
Note: a, b, cwere derived from Artesunate Amodiaquine. Artemether Lumefantrine and Dihydroartemisinin Piperaquine respectively
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Fig. 1 The percentages of ACTs made by each manufacturer in our market survey in central Ghana. In Fig. 1, is a bar chart, which illustrates the
manufacturers of ACTs found on the market in central Ghana. The ACTs from each manufacturer were expressed as percentages. The x-axis represents
the manufacturing companies whose ACT products were found in the market in central Ghana. The y-axis illustrates the percentage proportion of each
ACT produced by each manufacturer, among the identified manufacturing companies
Fig. 2 Percentage of the total number of substandard ACTs originating from each country of production. Fig. 2 is an illustration of the HPLC results of
ACTs by countries of manufacture. The x-axis represents the results whilst the y-axis indicates the percentage proportion for each country.
The portions of the graph coloured blue represent Indian manufacturing companies. The portions of the graph coloured red represent
Ghanaian manufacturing companies. The portions of the graph coloured green represent Chinese manufacturing companies. The portions of
the graph coloured violet represent Moroccan manufacturing companies
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Limitations
The data used in this study was from 8 out of the
current 216 districts in Ghana. There is the possibility
that actions and recommendations made based on the
findings of this survey may not be able to eradicate the
practice of importation into or manufacture of poor
quality ACTs in Ghana. This survey was, however, car-
ried out in typical districts in Ghana and therefore the
findings are deemed to be representative of the national
situation.
The non-disclosure of intent of the research team to
the sellers at the MOs and suppliers of the ACTs may
raise some concerns about the design of this study; but
recommendations of the ethics review committee on the
use of “mystery shoppers” were followed. Though dis-
closure of the full intent of the shoppers could have been
used, this may have triggered unwillingness of medicine
sellers to cooperate with our study team, as well as put
them in harm’s way. Our risk-benefit balance therefore
leaned towards non-disclosure of the identities of the
“mystery shoppers”.
Recommendations
To effectively combat proliferation of poor quality medi-
cines and ensure only high quality medications exist on
the Ghanaian market:
□ There should be first and foremost, mechanisms in
place for effective inter-country collaboration, since
much of the trade in poor quality medicines occurs
across national borders. There is the need for the
regulatory authorities in Ghana to map out all entry
points for imported medicines so that surveillance on
medicines imports can be more effectively deployed at
all entry points; ensuring that medicines entering
Ghana are registered and have passed appropriate
quality control testing. These measures will also require
that regulatory agencies are provided the much needed
personnel and equipment to work more effectively.
Additionally, advertisement and promotion of
medicines should be regulated as well.
□ The Ghana Food and Drugs Authority (GFDA)
should maintain a list of medicine manufacturers to
help it decide how monitoring and surveillance of ACT
quality could be tackled effectively. The entire medical
supply chain needs tightening to eliminate any
loopholes that may exist. Random surveys through the
open market should be regularly enforced to
quarantine all medicines that have not yet gone
through GFDA registration.
□ Legislation, including how medicines will be tested
for quality, should be updated and streamlined to keep
pace with the scale of the drug quality problem and to
provide a dissuasive deterrent to criminal activity. The
global health community and national governments will
need to engage with consumers so that patients
understand the importance of only buying medicines
through regulated outlets. Health care providers such
as physicians, nurses and pharmacist are well
positioned to help governments in this difficult fight by
reporting any suspicious ACTs that they come across
in their work. They can also educate their patients on
how to identify poor quality medicines by using visual
aids. Giving incentives to individuals who provide
critical information leading to the conviction of the
culprits of this crime may also be needed. Great
emphasis on the overall strategies suggested here
should be put in rural areas where current control and
monitoring of the medicine quality is generally more
challenging.
□ There should be regular testing on randomly-
selected antimalarials found in known outlets.
□ It is recommended that co-blistered ACTs be
banned, with only co-formulated ACTs remaining in
the Ghanaian market so as to improve patient
adherence.
Conclusions
No counterfeit ACTs were found when purchases were
made in the studied area, however, substandard ACTs
were very common. It was found that 35.4 % of the ACT
medicines sampled API content. About 9 % of the ACTs
for sale to community members at MOs had already
expired.
Though this work was carried out in eight typical dis-
tricts in Ghana, it is not expected that the results will be
different in other geographical areas in the country. It
can be inferred that there are major public health impli-
cations for Ghana and other malaria endemic countries
with such poor quality medicines flooding the health
systems. While ACTs are still highly efficacious for mal-
aria treatment in most cases, several factors detract from
their effectiveness. These not only include drug quality,
but also access to ACTs, prescriber compliance, and pa-
tient adherence. In areas with high percentages of sub-
standard or expired ACTs, there is worry that a fraction
of those who have access to ACTs for treatment will not
have their malaria treated appropriately, leading to con-
tinuing high levels of morbidity and mortality, loss of
days at work, excessive pressure and loss of confidence
on health systems, resorting to traditional remedy. All
organizations and individuals championing the message
of controlling, eliminating and eradicating malaria even-
tually need to be informed regarding the prevalence of
poor quality medicines.
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